About us

Scientific Team



Mike Westby PhD 

Mike has over 20 years' experience in Pharma R&D, having worked for both Roche and Pfizer. Mike has worked across the Research and Development spectrum and whilst at Pfizer he helped successfully develop a novel therapy for treatment of HIV infection. Mike also headed up Pfizer's Opportunities for Partnership in Medicine (OPM) Research Unit and was a member of the Research Leadership Team at Pfizer's R&D UK Laboratories. Mike trained in Molecular Biology and Biochemistry at University of Durham, obtained his PhD at Warwick University and then completed a postdoctoral research fellow at St George's Hospital Medical School.


Mel Glossop BSc (Hons), MRSC, CCHem

Mel Glossop has over 20 years’ experience in both Pharmaceutical R&D and Biotechnology environments. As a project synthetic leader for Pfizer Mel led multiple global chemistry teams, both in-house and externally to enable delivery of molecules from hit-to-lead through to candidate molecule scale up to support Phase 1.  Mel has contributed to the success of multiple drug candidates for the Pfizer pain portfolio and has extensive experience of working within multidisciplinary teams to deliver all aspects of chemistry. Mel graduated from the University of Southampton, is a chartered chemist from the RSC and is author and inventor on multiple patents and publications.


Sascha Kristian PhD

Sascha has been a long-term consultant to Centauri, including as the lead author on the first proof-of-principal Alphamer publication (conducted in partnership with Prof. Victor Nizet; see J. Mol. Med. 2015. 93(6):619-31). Sascha is a trained microbiologist with industry experience including five years at Kyowa Hakko Kirin California. While at Kirin, Sascha successfully designed, initiated, directed, and interpreted several proof-of-concept studies that proved the functional activity of antimicrobial candidate antibodies in vitro and in rodent models of infection which led to the identification of lead candidate antibodies for clinical development. Following his time at Kirin, Sascha became the Research Director of Translational Biology at Agalimmune where he led the drug development program for Alphaject (AGI134), a synthetic cancer immunotherapy for eliciting patient-specific, anti-tumor immune responses in multiple cancer types.


Jennifer Schneider PhD, MPH

Jennifer provides Business Development and policy support to Centauri Therapeutics, having worked with the Centauri team for many years. Jennifer provides expertise in antibiotic policy, partnering, and fund raising. She has helped companies secure over $5 billion in capital. Importantly in the antimicrobial space, Jennifer participates in US and international discussions surrounding market creation, access, and novel payment models.


Lyndsey Whitlock BSc (Hons)

Lyndsey has more than 20 years’ experience in Pharmaceutical R&D including having worked for Pfizer, Emergent BioSolutions, Takeda and a number of small biotech companies. Lyndsey has also been Project Manager at two Biotechs (Ziarco Pharma and Reneo Pharma). Lyndsey is responsible for the day-to-day project management of the project, as well as ensuring all progress reports and finance documents are submitted, including the arrangement and reporting of external audits.